Bioxodes Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series B
  • (In Progress)

  • Latest Deal Amount
  • $82.9M

  • Investors
  • 11

Bioxodes General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to prevent and treat thrombotic and inflammatory diseases. The company's platform prevents blood clot formation without increasing the risk of further bleeding, the way anticoagulants inhibit the activation of neutrophils, a type of white blood cell that often acts as the first responders of the inflammatory system, offers a balance between antithrombotic benefits and hemorrhagic side effects, enabling healthcare providers to prevent thrombosis.

Contact Information

Website
www.bioxodes.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • BioPark
  • Rue Santos-dumont, 1
  • 6041 Gosselies
  • Belgium
+32 071
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences
Corporate Office
  • BioPark
  • Rue Santos-dumont, 1
  • 6041 Gosselies
  • Belgium
+32 071

Bioxodes Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bioxodes Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 12-Feb-2025 $82.9M In Progress Clinical Trials - Phase 2
6. Later Stage VC (Series A) 10-Dec-2025 Completed Clinical Trials - Phase 1
5. Grant 21-Nov-2023 Completed Clinical Trials - Phase 1
4. Later Stage VC 24-Apr-2019 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A) 01-Jan-2015 Completed Clinical Trials - Phase 1
2. Seed Round 26-Nov-2013 $3.51M $3.51M Completed Startup
1. University Spin-Out 20-Apr-2010 Completed Startup
To view Bioxodes’s complete valuation and funding history, request access »

Bioxodes Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference
To view Bioxodes’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Bioxodes Patents

  • 48

    Total Documents Applications and Grants

  • Total Patents Families

  • 22

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Bioxodes Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026229540-A1 Stable ir-cpi compositions with extended shelf-life Pending 30-Apr-2025
AU-2023272308-A1 Ixodes ricinus salivary gland polypeptide for preventing and treating brain inflammation Pending 20-May-2022
EP-4493207-A1 Ixodes ricinus salivary gland polypeptide for preventing and treating brain inflammation Active 20-May-2022
EP-4493207-B1 Ixodes ricinus salivary gland polypeptide for preventing and treating brain inflammation Active 20-May-2022
ES-3069222-T3 Ixodes ricinus salivary gland polypeptide for preventing and treating brain inflammation Active 20-May-2022 A61K38/1767
To view Bioxodes’s complete patent history, request access »

Bioxodes Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bioxodes Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Newton BioCapital Venture Capital Minority
ORSA FUND Venture Capital Minority
Carbon ( Belgium ) Venture Capital Minority
European Regional Development Fund (Brandenburg) Government Minority
Angel (individual) Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Bioxodes FAQs

  • When was Bioxodes founded?

    Bioxodes was founded in 2010.

  • Where is Bioxodes headquartered?

    Bioxodes is headquartered in Gosselies, Belgium.

  • What is the size of Bioxodes?

    Bioxodes has 8 total employees.

  • What industry is Bioxodes in?

    Bioxodes’s primary industry is Biotechnology.

  • Is Bioxodes a private or public company?

    Bioxodes is a Private company.

  • What is the current valuation of Bioxodes?

    The current valuation of Bioxodes is .

  • What is Bioxodes’s current revenue?

    The current revenue for Bioxodes is .

  • How much funding has Bioxodes raised over time?

    Bioxodes has raised $39.1M.

  • Who are Bioxodes’s investors?

    Newton BioCapital, ORSA FUND, Carbon ( Belgium ), European Regional Development Fund (Brandenburg), and are 5 of 11 investors who have invested in Bioxodes.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process